Prognostic factors and adjuvant therapy in uterine carcinosarcoma

T. I. Wu, K. H. Hsu, H. J. Huang, S. Hsueh, H. H. Chou, C. S. Tsai, K. C. Ho, A. Chao, T. C. Chang, C. H. Lai

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5% and 33.8%, respectively for Stage I-IV. Distant site metastasis with/ without pelvic failure occurred in 83.3% of those with recurrence/ progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Issue number5
Publication statusPublished - 2008
Externally publishedYes


  • Chemoradiation
  • Chemotherapy
  • Malignant mixed müllerian tumor
  • Prognostic factor
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Prognostic factors and adjuvant therapy in uterine carcinosarcoma'. Together they form a unique fingerprint.

Cite this